AOD-9604 is a synthetic fragment of human growth hormone (hGH), specifically the C-terminal region (amino acids 176-191) with a modified tyrosine at the N-terminus. It was developed by Monash University in Australia with a specific goal: retain the lipolytic (fat-burning) activity of hGH while eliminating the insulin resistance and growth-promoting side effects that make full hGH problematic for metabolic use.
Research context only. The peptides and compounds discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
AOD-9604 is a synthetic HGH fragment studied for fat loss through targeted lipolysis. It stimulates fat cell breakdown via beta-3 adrenergic receptor activity without the insulin resistance, IGF-1 elevation, or growth-promoting side effects of full HGH. It has FDA GRAS status and went through Phase 3 clinical trials for obesity.
How Does AOD-9604 Work?
Full HGH drives fat loss through lipolytic activity — stimulating fat cells to release stored triglycerides. But HGH also antagonises insulin signalling (causing insulin resistance), stimulates IGF-1 production, and promotes tissue growth. For someone using HGH purely for fat loss, most of this activity is off-target.
AOD-9604 retains the HGH peptide fragment responsible for lipolytic signalling while removing the regions responsible for insulin antagonism and IGF-1 stimulation. This targeted mechanism means AOD-9604 can stimulate fat breakdown without raising blood glucose, causing insulin resistance, or promoting the growth effects of full HGH.
The primary mechanism involves beta-3 adrenergic receptor stimulation in adipose tissue, increasing cyclic AMP production in fat cells and driving lipolysis. AOD-9604 also appears to inhibit lipogenesis (new fat storage) by modulating fatty acid synthase activity.
What Does the Clinical Research Show About AOD-9604?
AOD-9604 was developed and taken into clinical trials by Metabolic Pharmaceuticals (later acquired by Calzada). The compound achieved Phase 3 clinical trials for obesity, making it one of the most clinically developed research peptides. The Phase 3 trial ultimately failed to show statistically significant weight loss versus placebo at the doses studied — a setback that led to discontinuation of commercial development.
The clinical trial results are nuanced: while the primary endpoint (total weight loss) was not met, secondary analyses showed fat mass reduction, particularly visceral fat. The compound received FDA GRAS (Generally Recognised As Safe) status for food and beverage use based on its safety profile, which is an unusual regulatory milestone for a research peptide.
Community protocols typically use higher doses or longer durations than the clinical trials, which may explain the disconnect between the trial results and anecdotal reports. The safety profile is well-established from the clinical programme.
What Is the Recommended AOD-9604 Dosage?
| Protocol | Dose | Route | Timing | Duration |
|---|---|---|---|---|
| Standard fat loss | 300 mcg/day | SubQ | Fasted AM | 12 weeks |
| Higher dose community protocol | 500 mcg/day | SubQ | Fasted AM | 8–12 weeks |
| Combined with GLP-1 | 250 mcg/day | SubQ | Fasted AM | Per physician |
What Are the Side Effects and Realistic Expectations for AOD-9604?
AOD-9604's safety profile is among the cleanest in the research peptide space — supported by actual Phase 3 clinical data rather than just animal studies and community reports.
**No insulin resistance:** The key advantage over full HGH. Blood glucose is not meaningfully affected in clinical studies. This makes AOD-9604 appropriate for people with metabolic concerns who want lipolytic support.
**No IGF-1 elevation:** Consistent with its fragment mechanism — no growth-promoting effects.
**Mild injection site reactions:** Occasional redness or mild pain at SubQ injection site. Transient and common with any peptide injection.
**Realistic fat loss expectations:** AOD-9604 is a lipolytic support tool, not a dramatic weight loss drug. Its clinical Phase 3 results should calibrate expectations — meaningful fat mobilisation in the right metabolic context but not equivalent to the dramatic effects of GLP-1 agonists. Most community users report better results in a caloric deficit with concurrent training.
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
AOD-9604 is a synthetic HGH fragment studied for fat loss through targeted lipolysis. It stimulates fat cell breakdown via beta-3 adrenergic receptor activity without the insulin resistance, IGF-1 elevation, or growth-promoting side effects of full HGH. It has FDA GRAS status and went through Phase 3 clinical trials for obesity.
The Phase 3 clinical trials did not meet their primary weight loss endpoint, which should calibrate expectations. However, fat mass reduction was observed in secondary analyses, and community reports at higher doses are generally positive. It works best as a lipolytic support tool in a caloric deficit — not as a standalone weight loss medication.
Essentially yes. Fragment 176-191 refers to the specific amino acid sequence from hGH, while AOD-9604 is the name used by Metabolic Pharmaceuticals for their clinical formulation with a modified N-terminal tyrosine. In practice they're used interchangeably in community protocols.
Fasted in the morning is the standard protocol. Insulin suppresses lipolysis, so injecting when insulin is low (after an overnight fast) maximises the fat-mobilising effect. Some protocols also inject pre-workout for the same reason.
Theoretically complementary — semaglutide reduces food intake and slows gastric emptying while AOD-9604 directly mobilises fat. Community protocols combining the two exist. Medical supervision is advisable for combined use given the potency of GLP-1 agonists.
No meaningful effect on muscle mass in either direction. The removal of the IGF-1-stimulating regions of HGH means AOD-9604 lacks the muscle-building activity of full HGH. This is both an advantage (no side effects) and a limitation (no anabolic benefit).